

№ п./п.	Name of the study	Год
	<b>URL</b>	
1	<b>Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vected Vaccines</b> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248264/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248264/</a>	2020
2	<b>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine a dose-escalation, open-label, non-randomised, first-in-human trial</b> <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext</a>	2020
3	<b>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</b> <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext</a>	2020
4	<b>A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes</b> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309451/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309451/</a>	2020
5	<b>Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption</b> <a href="https://www.nature.com/articles/s41591-020-0774-y">https://www.nature.com/articles/s41591-020-0774-y</a>	2020
6	<b>Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses</b> <a href="https://www.biorxiv.org/content/10.1101/2020.07.30.227470v1">https://www.biorxiv.org/content/10.1101/2020.07.30.227470v1</a>	2020
7	<b>The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism</b> <a href="https://www.biorxiv.org/content/10.1101/2020.07.20.213223v1">https://www.biorxiv.org/content/10.1101/2020.07.20.213223v1</a>	2020
8	<b>Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice</b> <a href="https://www.nature.com/articles/s41541-020-0200-y">https://www.nature.com/articles/s41541-020-0200-y</a>	2020
9	<b>Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein</b> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475872/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475872/</a>	2019
10	<b>State-of-the-art human adenovirus vectorology for therapeutic approaches</b> <a href="https://pubmed.ncbi.nlm.nih.gov/31758807/">https://pubmed.ncbi.nlm.nih.gov/31758807/</a>	2019
11	<b>Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor</b> <a href="https://advances.sciencemag.org/content/5/9/eaax3567">https://advances.sciencemag.org/content/5/9/eaax3567</a>	2019
12	<b>Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs</b> <a href="https://www.sciencedirect.com/science/article/pii/S0264410X19312307">https://www.sciencedirect.com/science/article/pii/S0264410X19312307</a>	2019
13	<b>Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates</b> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056916/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056916/</a>	2018

14	<b>Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge</b>	2018
	<a href="https://pubmed.ncbi.nlm.nih.gov/30142207/">https://pubmed.ncbi.nlm.nih.gov/30142207/</a>	
15	<b>Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys</b>	2018
	<a href="https://pubmed.ncbi.nlm.nih.gov/29793950/">https://pubmed.ncbi.nlm.nih.gov/29793950/</a>	
16	<b>First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector</b>	2018
	<a href="https://pubmed.ncbi.nlm.nih.gov/29669026/">https://pubmed.ncbi.nlm.nih.gov/29669026/</a>	
17	<b>Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus</b>	2018
	<a href="https://pubmed.ncbi.nlm.nih.gov/29739720/">https://pubmed.ncbi.nlm.nih.gov/29739720/</a>	
18	<b>Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть 1)</b>	2017
	<a href="https://www.mimmun.ru/mimmun/article/view/1216">https://www.mimmun.ru/mimmun/article/view/1216</a>	
19	<b>Разработка вакцин на основе аденовирусных векторов: обзор зарубежных клинических исследований (Часть 2)</b>	2017
	<a href="https://www.mimmun.ru/mimmun/article/view/1307">https://www.mimmun.ru/mimmun/article/view/1307</a>	
20	<b>Векторные вакцины против болезни, вызванной вирусом Эбола</b>	2017
	<a href="https://cyberleninka.ru/article/n/vektornye-vaktsiny-protiv-bolezni-vyzvannoy-virusom-ebola">https://cyberleninka.ru/article/n/vektornye-vaktsiny-protiv-bolezni-vyzvannoy-virusom-ebola</a>	
21	<b>Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle</b>	2017
	<a href="https://pubmed.ncbi.nlm.nih.gov/29076657/">https://pubmed.ncbi.nlm.nih.gov/29076657/</a>	
22	<b>Recent advances in genetic modification of adenovirus vectors for cancer treatment</b>	2017
	<a href="https://pubmed.ncbi.nlm.nih.gov/28266780/">https://pubmed.ncbi.nlm.nih.gov/28266780/</a>	
23	<b>32 - Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective</b>	2016
	<a href="https://www.sciencedirect.com/book/9780128002766/adenoviral-vectors-for-gene-therapy">https://www.sciencedirect.com/book/9780128002766/adenoviral-vectors-for-gene-therapy</a>	
24	<b>Adenoviral vector-based strategies against infectious disease and cancer</b>	2016
	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994731/#:~:text=and%20Dongming%20Zhou-,ABSTRACT,genetically%20modified%20for%20cancer%20therapy.">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994731/#:~:text=and%20Dongming%20Zhou-,ABSTRACT,genetically%20modified%20for%20cancer%20therapy.</a>	
25	<b>First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens</b>	2016
	<a href="https://pubmed.ncbi.nlm.nih.gov/28077588/">https://pubmed.ncbi.nlm.nih.gov/28077588/</a>	
26	<b>IMMUNOBIOLOGICAL DRUG AND METHOD FOR USING SAME FOR INDUCING SPECIFIC IMMUNITY AGAINST THE EBOLA VIRUS</b>	2016
	<a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016130047">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016130047</a>	
27	<b>Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats</b>	2015
	<a href="https://pubmed.ncbi.nlm.nih.gov/26319741/">https://pubmed.ncbi.nlm.nih.gov/26319741/</a>	

28	<b>High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial</b>	2015
	<a href="https://pubmed.ncbi.nlm.nih.gov/26333337/">https://pubmed.ncbi.nlm.nih.gov/26333337/</a>	
29	<b>Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy Malaria-Naïve adults</b>	2015
	<a href="https://pubmed.ncbi.nlm.nih.gov/26148007/">https://pubmed.ncbi.nlm.nih.gov/26148007/</a>	
30	<b>Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans</b>	2015
	<a href="https://pubmed.ncbi.nlm.nih.gov/25165165/">https://pubmed.ncbi.nlm.nih.gov/25165165/</a>	
31	<b>A Phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative african adults</b>	2015
	<a href="https://pubmed.ncbi.nlm.nih.gov/26252526/">https://pubmed.ncbi.nlm.nih.gov/26252526/</a>	
32	<b>A Phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults</b>	2015
	<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141687">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141687</a>	
33	<b>Immunization with Hexon Modified Adenoviral Vectors Integrated with gp83 Epitope Provides Protection against Trypanosoma cruzi Infection</b>	2014
	<a href="https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003089">https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003089</a>	
34	<b>First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)</b>	2014
	<a href="https://pubmed.ncbi.nlm.nih.gov/24719474/">https://pubmed.ncbi.nlm.nih.gov/24719474/</a>	
35	<b>Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial</b>	2014
	<a href="https://pubmed.ncbi.nlm.nih.gov/25007091/">https://pubmed.ncbi.nlm.nih.gov/25007091/</a>	
36	<b>A Human Type 5 Adenovirus-Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity</b>	2013
	<a href="https://pubmed.ncbi.nlm.nih.gov/24089406/">https://pubmed.ncbi.nlm.nih.gov/24089406/</a>	
37	<b>Viral vectors for vaccine applications</b>	2013
	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710930/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710930/</a>	
38	<b>Using Multivalent Adenoviral Vectors for HIV Vaccination</b>	2013
	<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060347">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060347</a>	
39	<b>Interleukin-Encoding Adenoviral Vectors as Genetic Adjuvant for Vaccination against Retroviral Infection</b>	2013
	<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082528">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082528</a>	
40	<b>Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-<math>\gamma</math> T cell responses in humans, Vaccine</b>	2013
	<a href="https://pubmed.ncbi.nlm.nih.gov/23357198/">https://pubmed.ncbi.nlm.nih.gov/23357198/</a>	
41	<b>Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum. Vaccin</b>	2013

	<a href="https://pubmed.ncbi.nlm.nih.gov/23899517/">https://pubmed.ncbi.nlm.nih.gov/23899517/</a>	
42	<b>A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age</b>	2013
	<a href="https://pubmed.ncbi.nlm.nih.gov/24244339/">https://pubmed.ncbi.nlm.nih.gov/24244339/</a>	
43	<b>First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine</b>	2013
	<a href="https://pubmed.ncbi.nlm.nih.gov/23125444/">https://pubmed.ncbi.nlm.nih.gov/23125444/</a>	
44	<b>DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity</b>	2013
	<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0055571">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0055571</a>	
45	<b>Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans</b>	2013
	<a href="https://www.sciencedirect.com/science/article/pii/S0264410X13000807">https://www.sciencedirect.com/science/article/pii/S0264410X13000807</a>	
46	<b>Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species</b>	2012
	<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0044115">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0044115</a>	
47	<b>Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man</b>	2012
	<a href="https://pubmed.ncbi.nlm.nih.gov/22218690/">https://pubmed.ncbi.nlm.nih.gov/22218690/</a>	
48	<b>Advances and future challenges in recombinant adenoviral vectored h5n1 influenza vaccines</b>	2012
	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509669/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509669/</a>	
49	<b>Adenovirus 5-vectored P.falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults</b>	2011
	<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024586">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024586</a>	
50	<b>A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)</b>	2011
	<a href="https://pubmed.ncbi.nlm.nih.gov/21857901/">https://pubmed.ncbi.nlm.nih.gov/21857901/</a>	
51	<b>The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert</b>	2010
	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067347/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067347/</a>	
52	<b>Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Response</b>	2010
	<a href="https://pubmed.ncbi.nlm.nih.gov/20126394/">https://pubmed.ncbi.nlm.nih.gov/20126394/</a>	
53	<b>Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus</b>	2009
	<a href="https://jvi.asm.org/content/83/23/12601">https://jvi.asm.org/content/83/23/12601</a>	
54	<b>Advanced Malignant Pleural or Peritoneal Effusion in Patients Treated with Recombinant Adenovirus p53 Injection plus Cisplatin</b>	2008
	<a href="https://pubmed.ncbi.nlm.nih.gov/19094436/">https://pubmed.ncbi.nlm.nih.gov/19094436/</a>	

55	<b>Adenoviruses: Malignant Transformation and Oncology</b>	2008
	<a href="https://www.sciencedirect.com/science/article/pii/B9780123744104003575">https://www.sciencedirect.com/science/article/pii/B9780123744104003575</a>	
56	<b>Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN- and antibody responses in mice</b>	2008
	<a href="https://www.sciencedirect.com/science/article/pii/S0264410X08004180">https://www.sciencedirect.com/science/article/pii/S0264410X08004180</a>	
57	<b>A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults, Vaccine</b>	2008
	<a href="https://pubmed.ncbi.nlm.nih.gov/18448211/">https://pubmed.ncbi.nlm.nih.gov/18448211/</a>	
58	<b>Role of MyD88 and TLR9 in the Innate Immune Response Elicited by Serotype 5 Adenoviral Vectors</b>	2007
	<a href="https://pubmed.ncbi.nlm.nih.gov/17685831/">https://pubmed.ncbi.nlm.nih.gov/17685831/</a>	
59	<b>Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine</b>	2007
	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077857/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077857/</a>	
60	<b>Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity</b>	2006
	<a href="https://pubmed.ncbi.nlm.nih.gov/16963747/">https://pubmed.ncbi.nlm.nih.gov/16963747/</a>	
61	<b>Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity</b>	2005
	<a href="https://pubmed.ncbi.nlm.nih.gov/19559110/">https://pubmed.ncbi.nlm.nih.gov/19559110/</a>	
62	<b>Adenoviral vectors: a promising tool for gene therapy</b>	2005
	<a href="https://pubmed.ncbi.nlm.nih.gov/16622281/">https://pubmed.ncbi.nlm.nih.gov/16622281/</a>	
63	<b>Good Manufacturing Practice Production of Adenoviral Vectors for Clinical Trials</b>	2005
	<a href="https://pubmed.ncbi.nlm.nih.gov/15812223/">https://pubmed.ncbi.nlm.nih.gov/15812223/</a>	
64	<b>Gene therapy clinical trials worldwide 1989–2004—an overview</b>	2004
	<a href="https://onlinelibrary.wiley.com/doi/10.1002/jgm.619">https://onlinelibrary.wiley.com/doi/10.1002/jgm.619</a>	
65	<b>Adenoviruses as Vaccine Vectors</b>	2004
	<a href="https://www.sciencedirect.com/science/article/pii/S1525001604013425">https://www.sciencedirect.com/science/article/pii/S1525001604013425</a>	
66	<b>Safety of Adenoviral Vectors: Results of Clinical Investigations in 445 Cancer Patients Treated with Advexin® (Adenoviral p53) Gene Therapy</b>	2004
	<a href="https://cyberleninka.org/article/n/1336451">https://cyberleninka.org/article/n/1336451</a>	
67	<b>Adenoviral vectors for gene transfer and therapy</b>	2004
	<a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/jgm.496">https://onlinelibrary.wiley.com/doi/abs/10.1002/jgm.496</a>	
68	<b>Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins</b>	2004
	<a href="https://jvi.asm.org/content/79/2/771">https://jvi.asm.org/content/79/2/771</a>	
69	<b>Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity</b>	2004
	<a href="https://pubmed.ncbi.nlm.nih.gov/15128818/">https://pubmed.ncbi.nlm.nih.gov/15128818/</a>	

70	<b>Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission</b>	2004
	<a href="https://www.nature.com/articles/7700765">https://www.nature.com/articles/7700765</a>	
71	<b>Production of adenovirus vector for gene therapy</b>	2002
	<a href="https://pubmed.ncbi.nlm.nih.gov/14550017/">https://pubmed.ncbi.nlm.nih.gov/14550017/</a>	
72	<b>Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response</b>	2002
	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459421/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459421/</a>	
73	<b>A New Vector System with Inducible E2a Cell Line for Production of Higher Titer and Safer Adenoviral Vectors</b>	2000
	<a href="https://pubmed.ncbi.nlm.nih.gov/10998335/">https://pubmed.ncbi.nlm.nih.gov/10998335/</a>	
74	<b>Human adenovirus type 5 vectors expressing rabies glycoprotein</b>	1996
	<a href="https://www.sciencedirect.com/science/article/pii/S0264410X96000126">https://www.sciencedirect.com/science/article/pii/S0264410X96000126</a>	
75	<b>Adenovirus vectors as recombinant viral vaccines</b>	1995
	<a href="https://www.sciencedirect.com/science/article/pii/0264410X9500032V#:~:text=Adenoviruses%20can%20efficiently%20induce%20immunity,have%20been%20constructed%20and%20tested.">https://www.sciencedirect.com/science/article/pii/0264410X9500032V#:~:text=Adenoviruses%20can%20efficiently%20induce%20immunity,have%20been%20constructed%20and%20tested.</a>	
76	<b>Gene therapy using adenoviral vectors</b>	1994
	<a href="https://www.sciencedirect.com/science/article/abs/pii/0958166994900841">https://www.sciencedirect.com/science/article/abs/pii/0958166994900841</a>	
77	<b>Adenoviruses as expression vectors and recombinant vaccines</b>	1990
	<a href="https://pubmed.ncbi.nlm.nih.gov/1366528/">https://pubmed.ncbi.nlm.nih.gov/1366528/</a>	